Relief Therapeutics/NeuroRx's Aviptadil Promise In COVID-19-Associated Respiratory Failure
Randomized Trial Results Expected Later This Quarter
Executive Summary
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.
You may also be interested in...
Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.